Disease relevance of Hemibody Irradiation

• Protection by WR-2721 of bone marrow (BM) from depression following hemibody irradiation (HBI) was assessed in patients receiving palliative therapy for widespread symptomatic metastasis on a Phase I/II Radiation Therapy Oncology Group (RTOG) protocol [1].
• For hemi-body irradiation, ondansetron (8 mg) and dexamethasone (8 mg) given orally produced complete control of emesis in 12 out of 14 patients [2].
• Twenty-four patients with limited disease small cell lung cancer (SCLC) were treated with sequential hemibody irradiation (SHB) integrated into a conventional chemotherapy-local radiotherapy (LRT) program [3].
• A patient with systemic histiocytosis was treated with hemibody irradiation, vincristine, and prednisone [4].
• Treatment of metastatic melanoma by 24-hour DTIC infusions and hemibody irradiation [5].

High impact information on Hemibody Irradiation

• The consolidation phase consisted of sequential hemi-body irradiation (HBI) (10 Gy per session, 6 weeks apart) in the first period (1988-June 1994) and sequential high-dose cyclophosphamide, etoposide, mitoxantrone+L-PAM and autologous haemopoietic stem cell transplantation in the second (July 1994-1999) [6].
• Further research to better define the clinical indications of hemibody irradiation and strontium-89 is recommended [7].
• The percent change in 5-HIAA excretion following upper/mid hemibody irradiation were greatest in Group A and smallest in Group C (p < 0.002) [8].
• The aim was to investigate the acute and later effects of lower hemibody irradiation on 5-HT turnover and the biological effect in the rat distal colon [9].
• In athymic mice, half-body irradiation was performed in an AECL Cobalt unit, at an SSD of 80 cm [10].

Chemical compound and disease context of Hemibody Irradiation

• The authors report the results of treatment of 41 patients with melphalan-resistant multiple myeloma using single half-body irradiation (HBI) or double half-body irradiation (DHBI) [11].
• The low response rate and high acute toxicity contraindicate the use of misonidazole with hemibody irradiation for palliation [12].

Associations of Hemibody Irradiation with chemical compounds

• As ondansetron was clearly effective in patients receiving hemibody irradiation it seems it would be prudent to adopt it for use in such patients routinely [13].
• Hemibody irradiation (HBI) was delivered after 1 or 3 courses of DTIC to the area of maximum disease in 23 patients [5].
• The radiation therapy oncology group conducted a phase I/II trial of hemibody irradiation combined with high-dose misonidazole in the management of metastatic solid tumors [12].

Gene context of Hemibody Irradiation

• This integrated program of systemic therapies with SHB and combination chemotherapy plus LRT is feasible for limited disease SCLC; it may prolong survival in patients who attain a CR but compared to similar programs without hemibody irradiation, there was no improvement in overall response rate, response duration, or survival [3].
• We describe a new and original therapy with total body irradiation in two separate 4 gy single courses (double hemibody irradiation) combined with GM-CSF support, 5ug/day on days 1-15 after each hemibody irradiation, for refractory patients with B-chronic lymphocytic leukemia (CLL) [14].

Analytical, diagnostic and therapeutic context of Hemibody Irradiation

• This retrospective study compares the results of treatment using hemibody irradiation (HBI) at the Royal Marsden Hospital (27 cases) with isotope therapy using the bone-seeking isotope strontium-89 (89Sr) at Southampton General Hospital (51 cases) [15].

References